Double Good, Triple Therapy Better in Endometrial Cancer? :

The fast pace of progress in endometrial cancer has taken a step forward with two trials underlining the benefit of immunotherapy plus chemo, while suggesting adding a PARP inhibitor could further boost outcomes.

Related Keywords

Texas , United States , Singapore , Bicocca , Sicilia , Italy , Pieris , Friuli Venezia Giulia , Milan , Lombardia , Valencia , Carabobo , Venezuela , Spain , Houston , Colombo , Western , Sri Lanka , Madrid , Genentech Roche , Nuvation Bio , Shannon Westin , Merck Serono , University Of Valencia , Boehringer Ingelheim , National University Cancer Institute , Jazz Pharmaceuticals , Caris , Novartis , European Society For Medical Oncology , Astrazeneca , Md Anderson Cancer Center , University Of Milan , Mario Negri Institute For Pharmacological Research , European Society , Medical Oncology , Annual Meeting , Clinical Oncology , Nicoletta Colombo , European Institute , Oncology Istituto , Carattere Scientifico , Cancer Center , Mario Negri Institute , Clovis Oncology , Karyopharm Therapeutics , Ellipses Pharma , Avenge Bio , Endometrial Carcinoma , Biologic Therapy , Breast Cancer , Alignant Breast Neoplasm , Chemotherapy , Ovarian Cancer , Alignant Ovarian Neoplasm , Immunotherapy , Cancer , Alignant Neoplasia , Arcinoma , Gynecological Cancers , Parp Inhibitors , Parp Inhibition , Oly Adp Ribose Polymerase Inhibitor , Toxicology , Tumor , Europe , European ,